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Summary
The D-type cyclins (cyclins D1, D2, and D3) are components of the core cell cycle machinery in mammalian cells. Cyclin
D3 gene is rearranged and the protein is overexpressed in several human lymphoid malignancies. In order to determine
the function of cyclin D3 in development and oncogenesis, we generated and analyzed cyclin D3-deficient mice. We
found that cyclin D3/ animals fail to undergo normal expansion of immature T lymphocytes and show greatly reduced
susceptibility to T cell malignancies triggered by specific oncogenic pathways. The requirement for cyclin D3 also operates
in human malignancies, as knock-down of cyclin D3 inhibited proliferation of acute lymphoblastic leukemias deriving from
immature T lymphocytes. These studies point to cyclin D3 as a potential target for therapeutic intervention in specific
human malignancies.
Introduction transcription factors and allows induction of E2F-target genes
that are required for the S phase entry (Dyson, 1998). Hence,
D-type cyclins are the ultimate recipients of mitogenic and onco- D cyclins lie at the interface between upstream oncogenic path-
genic signals. Three D cyclins (cyclins D1, D2, and D3) have ways and the retinoblastoma tumor suppressor protein.
been described in mammalian cells. The three proteins are en- Consistent with their growth-promoting functions, abnormal
coded by separate genes, but they show substantial amino acid expression of D cyclins is believed to be a driving force in several
similarity and are expressed in a highly overlapping fashion in human cancers. Indeed, chromosomal abnormalities involving
all proliferating cells (Sherr and Roberts, 1999). cyclin D loci and overexpression of cyclin D protein were ob-
Once induced, D cyclins bind and activate their associated
served in many malignancies. Cyclin D1 gene is rearranged orcyclin-dependent kinases CDK4 and CDK6 (Bates et al., 1994;
amplified and the protein is overexpressed in several humanKato et al., 1994; Meyerson and Harlow, 1994). Cyclin D-CDK
cancers such as breast carcinomas; squamous cell carcinomascomplexes phosphorylate the retinoblastoma tumor suppressor
of head and neck, esophagus, tongue, and larynx; carcinomasgene product, pRB, and pRB-related proteins p130 and p107
of uterine cervix; astrocytomas; non-small cell lung cancers; soft(Bates et al., 1994; Matsushime et al., 1992, 1994; Meyerson and
tissue sarcomas; mantle cell lymphomas; and others (Cheung etHarlow, 1994). This phosphorylation cancels growth-inhibitory
functions of pRB, leads to release or derepression of the E2F al., 2001; Fujii et al., 2001; Lammie et al., 1991; Withers et al.,
S I G N I F I C A N C E
D cyclins are the ultimate recipients of oncogenic signals. Amplification of the cyclin D genes and overexpression of cyclin D proteins
is seen in several human cancers. Importantly, a large number of human malignancies contain lesions in pathways impacting on
D cyclins. In this study, we found that mice lacking cyclin D3 show greatly reduced sensitivity to malignancies triggered by specific
oncogenic pathways in immature T lymphocytes. This requirement for cyclin D3 also operates in human malignancies, as knock-
down of cyclin D3 inhibited proliferation of T cell Acute Lymphoblastic Leukemia (T-ALL) cells. These studies illustrate the utility of
manipulating the mouse genome to understand the molecular pathways operating in human cancer cells, and they point to cyclin
D3 as a potential therapeutic target in human malignancies deriving from immature T lymphocytes.
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Figure 1. Targeted inactivation of the cyclin D3
gene
A: Cyclin D3 gene targeting strategy. The coding
exons are shown as filled boxes and are num-
bered; open boxes denote the noncoding por-
tions. Probe A used for Southern blot analysis, as
well as PCR primers G, A, and N3 are indicated.
Neo, the neomycin phosphotransferase gene;
TK, thymidine kinase gene. Arrows show tran-
scriptional orientation of these genes. Restriction
enzyme abbreviations: R, EcoRI; Bm, BamHI; N,
NruI; Bs, BssHII; Sm, SmaI; Sa, Sac II; E, EagI; A,
Asp718; Sp, SpeI; Sn, SnaBI; X, XbaI; Nh, NheI; Hp,
HpaI; Bp, BspEI; RV, EcoRV.
B: Southern blot analysis of genomic DNA ex-
tracted from ES cell clones, digested with EcoRI
and EcoRV and hybridized with probe A. The
position of wild-type (wt) and disrupted (KO) al-
leles are indicated.
C: PCR analysis of genomic DNA isolated from
mouse tails. The position of wild-type (wt) and
mutant (KO) amplification products are indi-
cated.
D: Immunoblot analysis of mouse embryo lysates
probed with anti-cyclin D3 antibody. In B, C, and
D, the genotypes are presented above the
lanes.
1991; Bartkova et al., 1994; Dickson et al., 1995; Weinstat- were fertile and appeared normal during the 1.5 year observation
period (data not shown). However, we noticed that cyclin D3/Saslow et al., 1995). Cyclin D2 gene is amplified in human
testicular tumors (Houldsworth et al., 1997; Sicinski et al., 1996), mice displayed severely hypoplastic thymuses (Figure 2A),
which contained 7-fold fewer thymocytes than wild-type lit-while the protein is overexpressed in a wide range of B cell
malignancies, such as B cell lymphocytic leukemias, lympho- termates (Figure 2B).
To further investigate the defect seen in cyclin D3-deficientplasmacytic lymphomas (Delmer et al., 1995), and chronic
lymphocytic leukemias (Motokura and Arnold, 1993). thymuses, we analyzed T cell development in mutant animals.
The great majority of T cells normally follow the developmentalCyclin D3 is the least studied of the D cyclins. It is expressed
in nearly all proliferating cells, and it shows the most broad sequence CD4CD8 (double-negative)→CD4CD8 (double-
positive)→CD4CD8 or CD4CD8 (single-positive). We foundexpression pattern of all three D-type cyclins (Bartkova et al.,
1998). Like other D cyclins, cyclin D3 is overexpressed in human that the percentage of double-negative cells was increased
while the fraction of double-positive cells was decreased in thecancers (Buschges et al., 1999; Hedberg et al., 2002; Ito et al.,
2001). A potential role for cyclin D3 in the malignancies of the thymuses of cyclin D3/ animals, as compared with wild-type
littermates (Figure 2C). When the absolute numbers of thymo-lymphoid system is suggested by the observations that cyclin
D3 gene is rearranged in several neoplastic diseases deriving cytes in each fraction were calculated, we found that the total
number of double-negative thymocytes was unchanged in mu-from this compartment, such as diffuse large B cell lymphomas
or multiple myelomas (Filipits et al., 2002; Shaughnessy et al., tant animals, as compared with wild-type littermates, while the
total number of double-positive cells was reduced over 12-fold2001).
In the present study, we tested the role for cyclin D3 in (Figure 2D).
development and in oncogenesis by generating cyclin D3-defi-
cient mice. We found that cyclin D3 is critically required for the Impaired expansion of immature T lymphocytes
The expansion of immature T lymphocytes within the thymusproliferative burst during development of immature T lympho-
cytes. Importantly, we found that cyclin D3 is essential for spe- normally occurs at the double-negative stage (Muljo and Schlis-
sel, 2000). The double-negative population can be further subdi-cific oncogenic pathways operating in this compartment. Lastly,
we demonstrate that this requirement for cyclin D3 also extends vided into four developmental stages, termed DN-1 to DN-4.
Up to the DN-3, the proliferation of thymocytes is driven by theto human malignancies deriving from immature T lymphocytes.
These studies raise a possibility of novel therapeutic approaches interleukins and c-kit (Di Santo et al., 2000). A dramatic shift
takes place at the DN-3 stage. At this point, immature lympho-in human T cell leukemias, centered on cyclin D3 inhibition.
cytes rearrange  chains of their T cell receptor (TCR) and
assemble the pre-TCR. The proliferation of thymocytes be-Results
comes cytokine independent, but it is driven instead by the
pre-TCR (Fehling et al., 1995; Hoffman et al., 1996). SignalsThymocyte defects in cyclin D3-deficient mice
Cyclin D3/ mice were generated by gene targeting in em- emanating from the pre-TCR drive expansion of the DN-4 and of
“immature single-positive” (ISP) cells, which finally differentiatebryonal stem cells, using standard procedures (Figure 1). Cyclin
D3-deficient animals were born with expected frequency; they into double-positive thymocytes and arrest their proliferation.
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Figure 3. Impaired expansion of immature T lymphocytes in cyclin D3-defi-Figure 2. Defective thymocyte development in cyclin D3-deficient mice
cient mice
A: Appearance of thymuses dissected from 5-week-old wild-type (wt) and
A: Percentage of cells in the S phase of the cell cycle among subsets ofcyclin D3-deficient mice. Magnification 6.
double-negative (DN) and immature single-positive (ISP) thymocytes. TheB: Total number of thymocytes in 4- to 6-week-old wild-type (n  11) and
assembly of the pre-TCR is indicated. Shown are means of four independentcyclin D3/ (n  11) mice. Error bars denote SD.
experiments, each using pooled thymocytes from 5 mice, 4–6 weeks old.C: Examples of flow cytometric profiles of thymocytes from 5-week-old mice
Error bars indicate SD.stained with anti-CD4 and anti-CD8 antibodies. The percentage of cells in
B: Western blot analysis of thymocyte subsets from wild-type mice. Uppereach quadrant is shown.
and lower panels represent the same blot sequentially probed with antibod-D: Total number of CD4CD8 double-negative (DN), CD4CD8 double-
ies against cyclin D3 and D2. DP denotes double-positive cells.positive (DP), CD4, and CD8 thymocytes in 4- to 6-week-old wild-type
C: Northern blot analysis of RNA prepared from indicated thymocyte subsets(n  8) and cyclin D3/ mice (n  9). Error bars denote SD.
from wild-type mice probed with a cyclin D3-specific probe. Ethidium-bro-
mide-stained gel is shown below (loading control).
D: Rag2/ mice were injected intraperitoneally with anti-CD3 antibody.
Thymocytes were harvested at 0, 12, and 18 hr after stimulation, and cyclin
To probe the proliferation rate of mutant thymocytes, we D3 levels were determined by the Western blotting. A cross-reacting band
is shown below (loading control). To ensure equal loading, Western blotsflow-sorted double-negative cells into DN-1–DN-4 and ISP pop-
were reprobed with an anti-actin antibody.ulations, and we determined the percentage of proliferating cells
E: Rag2/ or Rag2//cyclin D3/ mice were injected intraperitoneally with
in each population. We found that the fraction of cycling cells anti-CD3 antibody. Four days after stimulation, thymocyte numbers were
at the DN-1, DN-2, and DN-3 did not differ significantly between determined and compared with thymocyte counts in untreated animals.
The values were: untreated Rag2/  0.35  106; untreated Rag2//cyclinwild-type and cyclin D3-deficient mice (Figure 3A), revealing
D3/  0.37  106; treated Rag2/  24.0  106; treated Rag2//cyclinthat cyclin D3 is dispensable for cytokine-driven expansion of
D3/  0.42  106. Four to five mice were analyzed for each time point.
immature T lymphocytes. In contrast, the pre-TCR-driven Error bars indicate SE.
expansion of the DN-4 and ISP thymocytes was very reduced in
cyclin D3-deficient mice (Figure 3A). Importantly, we determined
that cyclin D3-deficient thymocytes expressed normal levels of
TCR and of other pre-TCR components (data not shown). To address this issue further, we quantified the expression
Collectively, these observations suggest that cyclin D3 might of cyclin D3 protein in sorted double-negative populations of
operate downstream of the pre-TCR in driving proliferation of wild-type mice, using Western blotting. We found that cyclin
immature T lymphocytes, and that in the absence of cyclin D3, D3 was strongly induced at the DN-4 and the ISP stages, i.e.,
the normally assembled pre-TCR fails to drive expansion of following pre-TCR assembly (Figure 3B, upper panel). In con-
trast, cyclin D2 expression was high at cytokine-dependentimmature thymocytes.
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stages (DN-1 to DN-3) but was essentially absent once TCR
rearrangements took place (Figure 3B, lower panel). No expres-
sion of cyclin D1 was detected in the thymocytes (data not
shown).
Northern blot analyses revealed a strong induction of cyclin
D3 mRNA at the DN-4 stage, consistent with increased protein
levels (Figure 3C). These observations reinforced the notion that
cyclin D3 might be a critical downstream target of the signaling
pathways emanating from the pre-TCR.
We next took advantage of mice deficient in recombinase-
activating gene (Rag). The thymocytes of these animals are
arrested at the DN-3 stage (Mombaerts et al., 1992; Shinkai et
al., 1992). This arrest can be overcome by administration of
anti-CD3 antibodies, which mimics the signaling from the pre-
TCR (Levelt et al., 1993; Shinkai and Alt, 1994). We injected
Rag-2-deficient mice with anti-CD3 and determined the ex-
pression of cyclin D3 following the stimulation. Administration
of anti-CD3 antibodies led to rapid induction of cyclin D3 (Fig-
ure 3D). This finding further supports our hypothesis that cyclin
D3 operates downstream of the pre-TCR.
We next crossed Rag-2-deficient mice with cyclin D3/
animals and we generated double-knockout Rag2//cyclin
D3/ animals. These mice, along with Rag2/ mice, were
injected with anti-CD3 antibody, and we monitored the re-
sponse. As expected, Rag2/ mice responded with rapid cyclin
D3 induction followed by a proliferative burst that led to approxi-
mately 60-fold increase in thymocyte numbers. In contrast, thy-
mocyte expansion was virtually absent in Rag2/ mice lacking
cyclin D3 (Figure 3E). This result further confirms that cyclin D3
is critically required for pre-TCR-driven expansion of immature
thymocytes.
Cyclin D3 operates downstream of proto-oncogene
p56LCK kinase Figure 4. Cyclin D3 operates downstream of p56LCK kinase
The signaling pathways operating downstream of the pre-TCR A: Western blot analyses of sorted DN-3 and DN-4 thymocytes derived from
are not fully elucidated. However, it is well established that wild-type (wt) or p56LCK/ mice. Upper and lower panel represent the same
blot sequentially probed with antibodies against cyclin D3 and D2.proto-oncogene tyrosine kinase p56LCK signals downstream of
B: Northern blot analysis of p56LCK-deficient Jurkat derivative infected withthe pre-TCR and plays a key role in transducing mitogenic sig-
an empty vector (VECTOR) or with a retrovirus expressing activated p56LCK
nals (Fehling et al., 1997; Levelt et al., 1995; Molina et al., 1992; (LCK). Blots were probed with a cyclin D3-specific probe and were reprobed
Mombaerts et al., 1994). We noted that the developmental ab- with glyceraldehyde-3-phosphate dehydrogenase cDNA (loading control).
C: Cyclin D3 levels in p56LCK-overexpressing thymic lymphoma cell linenormalities in thymuses of cyclin D3-deficient mice bear strong
LGF2046. Cells were treated overnight with PP1, and inhibitor of p56LCK. Theresemblance to the phenotype of mice lacking p56LCK (Levelt et
inhibitor was then washed off and the levels of cyclin D3 were followed byal., 1995; Molina et al., 1992). Hence, we hypothesized that
Western blotting. Blots were reprobed with anti-CDK4 antibody (loading
cyclin D3 might operate downstream of p56LCK. To address this control).
issue experimentally, we first sorted DN-3 and DN-4 thymocytes D: Comparison of tumor susceptibility between p56LCK/cyclin D3/ (n  10)
and p56LCK/cyclin D3/ (n  12) mice.from p56LCK-deficient and from control, wild-type mice, and we
E: Expression of D cyclins in p56LCK-triggered tumors arising in cyclin D3/determined the levels of cyclin D3 using Western blotting. As
and cyclin D3/ animals. Western blots were probed with antibodies
expected from our previous analyses, in wild-type mice we against cyclins D3, D2, and D1 and with anti-actin antibody (loading
detected a strong induction of cyclin D3 at the DN-4 stage. In control).
contrast, this induction was essentially absent in mice lacking
p56LCK (Figure 4A). Hence, genetic ablation of p56LCK abolished
the induction of cyclin D3 after the pre-TCR formation, sug-
gesting that the induction of cyclin D3 is controlled via p56LCK- together with a cyclin D3-promoter-reporter construct resulted
dependent pathway. in over 3-fold induction of the cyclin D3 promoter (data not
To further explore this notion, we compared cyclin D3 mRNA shown).
and protein levels in the p56LCK-deficient Jurkat T cell leukemia Lastly, we tested the connection between p56LCK and cyclin
D3 using two p56LCK-transformed thymoblast cell lines, LGF2046cell line, J.CaM, and in J.CaM cells that we engineered to ex-
press activated p56LCK. We found that ectopic expression of and LGF10442. These lines were derived from a thymic lym-
phoma arising in transgenic mice overexpressing activatedactivated p56LCK led to strong upregulation of cyclin D3 (Figure
4B). These findings were further strengthened by our observa- p56LCK in immature T cells (Abraham et al., 1991; Lin and Abra-
ham, 1997). The proliferation of these cells is critically dependenttion that cotransfection of the constitutively active form of p56LCK
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on p56LCK (S.D.L., unpublished observations). To determine the
time frame of cyclin D3 induction in response to p56LCK, we
treated thymoblast cells overnight with PP1, an inhibitor of
p56LCK (and of other Src family of kinases), thereby arresting cell
proliferation. We next washed off the inhibitor, thereby triggering
p56LCK activation, and followed cyclin D3 levels by Western blot-
ting. We found that cyclin D3 was strongly induced as early as
2 hr after triggering the kinase activity of p56LCK (Figure 4C),
well before any changes in proliferative status of cells could be
observed (data not shown), again pointing to a direct link be-
tween p56LCK signaling and cyclin D3. Collectively, our results
suggest that cyclin D3 represents a critical target of the pre-
TCR→p56LCK pathway operating within immature T cells.
Requirement for cyclin D3 in mouse T cell malignancies
The observed role for cyclin D3 in T cell development prompted
us to investigate the requirement for cyclin D3 in oncogenesis
of this cellular compartment. To address this issue, we utilized
three mouse models of T cell malignances: two involving the
pre-TCR→p56LCK-dependent pathway and one pre-TCR-inde-
pendent pathway. First, we crossed cyclin D3-deficient mice
with mice overexpressing p56LCK. These transgenic mice are
highly prone to T cell tumors due to targeted overexpression
of p56LCK in immature thymocytes (Abraham et al., 1991).
As expected (Abraham et al., 1991), cyclin D3//p56LCK
transgenic mice rapidly developed T cell malignancies and died
starting at 7 weeks of age. In contrast, the incidence of tumors
was delayed by 6–8 weeks in cyclin D3//p56LCK mice and the
survival time was nearly doubled (Figure 4D).
In order to understand a bypass mechanism that eventually
allowed delayed tumor appearance in cyclin D3-deficient mice,
we analyzed the expression pattern of D cyclins in tumors arising
in wild-type and cyclin D3/ mice. Our analyses revealed that Figure 5. Occurrence of T cell malignancies in cyclin D3/ mice
tumors found in wild-type mice expressed high levels of cyclin A: Cyclin D3/ or cyclin D3/ lineage-negative bone marrow cells were
transduced with retroviruses encoding constitutively active intracellular do-D3 but only low levels of cyclins D2 and D1. In contrast, tumors
main of Notch1-IRES-EGFP or IRES-EGFP, and the cells were injected intoarising in cyclin D3/ animals lacked cyclin D3 (as expected),
irradiated Rag2/c/ recipients. Bone marrow cells collected from 12but instead expressed greatly elevated levels of cyclin D2 (Figure
cyclin D3/ donors were used to reconstitute 6 recipients, while bone mar-
4E). Importantly, both cyclin D3/ and cyclin D3/ tumors row cells from 14 cyclin D3/ mice were used to reconstitute 8 recipients.
were of the same immunophenotype (CD4CD8CD25CD44, Incidence of leukemia (presence of CD4CD8 leukemic cells in the periph-
eral blood) is indicated; all cyclin D3/ mice died at 11–13 weeks anddata not shown). We interpret these findings as an indication
presented multiple tumors. None of cyclin D3/ mice had any tumors atthat in the absence of cyclin D3, p56LCK can drive tumor cell
the end of observation period (22 weeks).
proliferation via cyclin D2. B: Upper panels: total, GFP-positive, and GFP-negative peripheral blood
We extended these analyses using another model of T cell lymphocytes were stained with antibodies against TCR and analyzed by
flow cytometry. Lower panels: peripheral blood lymphocytes were stainedmalignancy, namely leukemias induced by the activated, intra-
with antibodies against CD4 and CD8, gated on GFP-positive cells, andcellular (IC) form of the Notch. This model is believed to be
analyzed by flow cytometry.
reminiscent of human childhood T cell acute lymphoblastic C: Comparison of tumor susceptibility between p53//cyclin D3/ (n  8)
leukemias (T-ALL) (Bellavia et al., 2000). Importantly, it is well and p53//cyclin D3/ (n  10) mice.
established that Notch-driven leukemogenesis critically requires
pre-TCR signaling, as mice lacking pre-TCR components are
resistant to Notch-induced leukemias (Allman et al., 2001; Bel-
transduction (Figure 5A). Peripheral blood leukemias persistedlavia et al., 2002). In our experimental approach, we collected
until 11–13 weeks, when all mice died due to presence of multi-bone marrows from wild-type and cyclin D3-deficient animals,
ple T cell tumors. In striking contrast, mice reconstituted withsorted their hematopoietic progenitor cells (HPC), and infected
Notch-expressing cyclin D3/ bone marrow remained leuke-the HPC with retroviruses encoding Notch1 together with GFP
mia-free throughout the entire observation period (Figure 5A).(Aster et al., 2000; Pui et al., 1999). These infected cells were
Importantly, we verified that the transduced cyclin D3/injected into sublethally irradiated recipients. As expected (Aster
bone marrow cells contributed to the T cell compartment in theet al., 2000; Pui et al., 1999), infection of wild-type bone marrow
recipient animals. Analyses of peripheral blood revealed thatwith activated Notch led to appearance of T-ALL leukemias
GFP-positive (i.e., transduced by Notch-IC) cyclin D3/ cells(presence of CD4CD8double-positive T cells in the peripheral
blood) in 100% of recipient mice 2 weeks after bone marrow give rise to mature peripheral CD4CD8 and CD4CD8 T
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lymphocytes. These peripheral T cells expressed surface TCR,
an indication that normal pre-TCR selection took place (Figure
5B). In contrast, wild-type cells transduced with Notch-IC gave
rise to double-positive leukemic cells (Figure 5B).
Collectively, these results indicate that cyclin D3 is required
for Notch oncogenic pathway that signals through pre-TCR, as
well as for p56LCK pathway that signals downstream of the
pre-TCR.
We next asked whether a similar requirement for cyclin D3
operated in pre-TCR-independent T cell malignancies. We took
advantage of p53-deficient mice that develop T cell tumors in
a pre-TCR-independent fashion (Liao et al., 1998; Nacht and
Jacks, 1998). Importantly, these tumors involve malignant trans-
formation of the very same T cell subsets (double-positive) as
pre-TCR-dependent Notch-driven tumors (Liao et al., 1998;
Nacht and Jacks, 1998; Pui et al., 1999). We crossed cyclin
D3/ mice with p53-deficient animals and generated cyclin
D3/p53/ animals. These cyclin D3/p53/ animals dis-
played normal tumor susceptibility and developed T cell malig-
nancies with similar kinetics as p53/ mice (Figure 5C). Hence,
cyclin D3 is dispensable for this pre-TCR-independent T cell
oncogenic pathway.
It should be noted, however, that while our analyses point
to a requirement for cyclin D3 in pre-TCR-dependent mouse
T cell leukemias, the continued expression of cyclin D3 in these
tumors may eventually become pre-TCR independent. Thus,
pre-TCR signaling was shown to interfere with the activity of
E2A transcription factor, via induction of an inhibitory protein,
Id3 (Engel and Murre, 2001), and this may contribute to cyclin
D3 induction. On the other hand, activated Notch can also inhibit
E2A activity (Ordentlich et al., 1998), thereby mimicking some
aspects of pre-TCR signaling, and this action may result in
pre-TCR-independent expression of cyclin D3 in Notch-driven
tumors.
Figure 6. Expression of cyclin D3 in human T cell acute lymphoblastic leu-
kemiasExpression of cyclin D3 in human T-ALL
A: A detailed view of the hierarchical tree of genes (rows) clustered acrossThe specific requirement for cyclin D3 function in murine leuke-
39 T cell leukemia samples (columns) focused on the cluster of genes con-mias prompted us to investigate the requirement for cyclin D3 taining cyclin D3. The normalized expression value for each gene is indi-
in human T cell malignancies. We decided to focus on T cell cated, red representing higher expression and green representing lower
expression. Cyclin D3 and p56LCK are underlined.acute lymphoblastic leukemias (T-ALL), since this malignancy
B: Differential expression of cyclin D3, p56LCK, TCR, and cyclin D2 (rows)is believed to arise predominantly from cells corresponding to
across T-ALL leukemia samples (columns) arranged according to knownimmature thymocytes. We started our analyses by performing developmental stages of T cell maturation. Samples expressing LYL1 onco-
“data mining” on the published global pattern of gene expres- gene are associated with an early arrest at the double-negative stage of
T cell differentiation prior to pre-TCR expression, while HOX11- and TAL1-sion in 39 cases of T-ALL (Ferrando et al., 2002). We first con-
positive samples are arrested at the early cortical and late cortical stagesducted a “nearest neighbor” analysis, to determine which genes
of thymocyte differentiation, respectively (Ferrando et al., 2002). The nor-show expression most closely correlating with the expression
malized expression value for each gene is indicated, with red representing
of cyclin D3. Strikingly, we found that among the 6817 genes higher expression and blue representing lower expression.
C: Absolute fluorescence values of cyclin D2 and cyclin D3 across all T-ALLanalyzed, p56LCK scored among the top ten genes most closely
samples.associated with cyclin D3; the association was very strong (coef-
ficient of the log expression values  0.77). Hierarchical cluster
analysis, shown in Figure 6A, illustrates the highly similar expres-
sion profiles of cyclin D3 and p56LCK in all 39 tumors. Signifi-
pro-T cells displayed low expression levels of the three genescantly, among other genes within the cyclin D3 cluster, there
(Figure 6B).are two direct targets for p56LCK in the pre-TCR pathway, namely
Comparison of absolute cyclin D3 levels with those of cyclinCD3 and ZAP-70 (Figure 6A) (Muljo and Schlissel, 2000).
D2 revealed that leukemias corresponding to pro-T cells ex-Analysis of T-ALL tumors arranged according to develop-
pressed high levels of cyclin D2 together with low levels of cyclinmental stage (Ferrando et al., 2002) revealed that cyclin D3,
D3. In contrast, more mature leukemias corresponding to pre-p56LCK, and TCR were highly expressed in leukemias deriving
T cells and double-positive cells often expressed cyclin D3 asfrom later (after pre-TCR formation) stages of T cell development
(Figure 6B). In contrast, T-ALL cases deriving from the very early a sole D-type cyclin (Figure 6C). This pattern very closely mirrors
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Figure 7. Requirement for cyclin D3 in human
T cell acute lymphoblastic leukemias
A: Western blot analysis of the levels of D cyclins
in Hela cells infected with an empty vector or
with vector encoding cyclin D3 siRNA. Blots were
also probed with anti-actin antibody (loading
control).
B: Twelve T-ALL cell lines deriving from immature
T cells with rearranged TCR chains were in-
fected with retroviruses encoding siRNA against
cyclin D3, and the impact on cell proliferation
was scored by propidium iodide staining fol-
lowed by FACS. Shown are results from five T-ALL
cell lines. Similar results were seen in remaining
seven T-ALL lines (see Experimental Procedures).
C: For control, we used two T-ALL deriving from
	 lineage of T cells and four B cell leukemias.
Shown is one 	 T-ALL line (PEER) and two B cell
leukemias (DAUDI and 2138C). Similar results
were seen in the remaining lines (see Experimen-
tal Procedures).
the expression seen by us in normal thymocyte development that this siRNA was cyclin D3 specific, i.e., it did not affect levels
of cyclins D1 or D2 (Figure 7A). We next gauged the impact of(Figure 3B). Hence, the specific expression pattern of D cyclins,
p56LCK, and TCR, seen during lymphocyte development, is cyclin D3 knock-down on cell proliferation by comparing cell
cycle distribution of cells infected with vectors encoding cyclinlargely preserved in malignancies deriving from distinct develop-
mental stages. D3 siRNA versus cells infected with empty vectors. We found
that knock-down of cyclin D3 significantly inhibited proliferation
of all 12 human immature T-ALL lines (Figure 7B, and data notRequirement for cyclin D3 in human T-ALL
shown). For control, we used two T-ALL cell lines derived fromLastly, we asked whether the requirement for cyclin D3 in onco-
T lymphocytes of the 	 lineage and four lines derived from Bgenic proliferation, demonstrated by us in mouse T cell malig-
lymphocytes. Our analyses revealed that the proliferation ofnancies, also operated in human T-ALL cells. To this end, we
these six control cell lines was not significantly affected bycollected 12 T-ALL cell lines (see Experimental Procedures)
the knock-down of cyclin D3 (Figure 7C, and data not shown).corresponding to immature thymocytes with rearranged TCR
chains, and we cultured them in vitro. We next infected the cells Collectively, these results indicate that cyclin D3 is critically
required for proliferation of human T-ALL deriving from imma-with retroviruses expressing siRNA against cyclin D3. Western
blot analyses confirmed a significant reduction of cyclin D3 ture T cells, as an acute ablation of cyclin D3 blocks their prolifer-
ation.levels following siRNA expression (Figure 7A). We also verified
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Discussion least one D cyclin must be present to allow normal cell division.
An exception to the rule is provided by the observation that
While amplification of the cyclin D genes and overexpression tumor cells that lost the retinoblastoma protein no longer require
of cyclin D proteins were reported in several human malignan- D cyclins, an indication that pRB is the major target for D cyclins
cies, a large number of human cancers contain lesions in path- in cell cycle progression (Sherr and Roberts, 1999). However,
ways impacting on D cyclins (Ortega et al., 2002). For this rea- the dependence of cancer cells on D cyclins has not been
son, elucidation of the normal functions of D cyclins is critically systematically analyzed. A recent demonstration that CDK2 ac-
important to understand the role of these proteins in human tivity is dispensable in cancer cells suggests that these tumor
tumorigenesis. cells can proliferate in the absence of certain cell cycle activators
In the present work, we analyzed the functions of cyclin D3 (Tetsu and McCormick, 2003). Importantly, cyclin D-CDK4 ki-
by generating and studying cyclin D3-deficient mice. The very nase activity was shown to be critically required for the prolifera-
specific developmental defect that we observed in cyclin D3 tion of the very same cancer cell lines (Tetsu and McCormick,
null animals led us to analyze the exact molecular pathway that 2003). It should be noted that the majority of tumor cells express
impinges on cyclin D3 in immature T lymphocytes. Through two or even all three D cyclins (Bartkova et al., 1998). Since the
combination of genetic crosses, in vivo studies of mice lacking three D cyclins are believed to perform overlapping, redundant
particular signaling molecules (p56LCK, TCR), and in vitro cell functions in cell cycle progression (Sherr and Roberts, 1999),
and molecular analyses, we determined that cyclin D3 is the one would have to target all D cyclins expressed by the tumor
major downstream target of the pre-TCR→p56LCK pathway. to arrest cancer cell proliferation.
The specific requirement for cyclin D3 is restricted to this The demonstration that a subset of T-ALL expresses cyclin
particular signaling pathway, as cytokine-driven expansion of D3 as a sole D cyclin and critically depends on this cyclin for
immature T cells proceeds normally in the absence of cyclin D3 proliferation offers a unique window of opportunity to use anti-
(Figure 3A). Moreover, peripheral T lymphocytes isolated from cyclin D3 therapy in selected human lymphoid malignancies.
cyclin D3 null animals proliferate normally in response to TCR We propose that targeting of a single D cyclin might not be of
stimulation (data not shown), again highlighting a very specific use in many human tumors that depend on multiple D cyclins
requirement for cyclin D3 downstream of “pre-receptor” pre- (or do not require D cyclins at all). On the other hand, malignan-
TCR signaling, but not in signaling downstream of mature TCR. cies do exist where the driving oncogenic pathway signals to
The critical role for cyclin D3 in transmitting pre-TCR-depen- the cell cycle machinery selectively via a specific D cyclin. These
dent mitogenic signals prompted us to analyze the requirement malignancies need to be identified, as they represent prime
for cyclin D3 in specific oncogenic pathways operating in imma- candidates for anti-cyclin D therapies. Given a very narrow phe-
ture T cells. Again, we found that cyclin D3 is essential for notype of cyclin D3-deficient mice, demonstrated here, and
oncogenic pathways operating downstream of the pre-TCR, equally circumscribed impact of the loss of cyclins D1 (Fantl et
while it is dispensable for a pre-TCR-independent pathway. al., 1995; Sicinski et al., 1995) or D2 (Sicinski et al., 1996), we
Specifically, we observed that mice lacking cyclin D3 are resis- hypothesize that agents, which cripple function of particular D
tant to Notch-driven leukemias and show reduced susceptibility cyclins, might be highly selective in shutting off the proliferation
to T cell malignancies triggered by p56LCK but remain fully sus- of selected human malignancies, while sparing other tissues.
ceptible to a pre-TCR-independent oncogenic pathway. These We propose that human T-ALL deriving from immature T lym-
studies extend our earlier, published observations that mice phocytes are good candidates for a therapeutic strategy cen-
lacking another component of the cell cycle machinery, cyclin tered around cyclin D3 inhibition.
D1, are resistant to Ras- and Neu-driven breast cancers, while
being fully susceptible to Wnt-1- and Myc-driven breast tumori- Experimental procedures
genesis (Yu et al., 2001). Collectively, this work establishes that
Generation of cyclin D3-deficient micedifferent D cyclins are critically required for tumorigenesis in
Cyclin D3 gene-targeting construct was assembled in pPNT vector by remov-specific tissues (cyclin D1, breast; cyclin D3, immature T cells),
ing a 1.4 kb BssH II-Spe I fragment of the murine cyclin D3 gene (containingand they represent key downstream components of defined
coding exons I and II) and replacing it with the neomycin phosphotransferase
oncogenic pathways (Neu→Ras in case of cyclin D1; pre- gene. The construct was electroporated into embryonal stem (ES) cells and
TCR→p56LCK in case of cyclin D3). recombinant clones were selected. 18 out of 146 ES cell clones analyzed
In the current study, we extended our analyses to human underwent homologous recombination at the cyclin D3 locus. Two of these
clones contributed to the germline tissue when mutant mice were generatedmalignancies. We found that human T-ALL with rearranged
using standard procedures (Sicinski et al., 1995). For the genotyping, geno-TCR chains critically require cyclin D3, as knock-down of this
mic DNA was digested with Eco RI and Eco RV and analyzed by Southernprotein inhibited the proliferation of tumor cells. Importantly,
blotting using a 650 bp Xba I-BspE I fragment of the cyclin D3 gene (probeknock-down of cyclin D3 had no impact on proliferation of two
A in Figure 1A). Alternatively, genomic DNA was PCR amplified using cyclin




B cell leukemias (Figure 7C and data not shown). Collectively, CCTGCGATGGCTCAC-3
) and a neo gene-specific primer N3 (5
-TGC
these results reveal a requirement for cyclin D3 function in a TGTCCATCTGCACGAGA-3
) by denaturing the DNA at 94C for 3 min,
followed by 36 cycles of amplification: 94C for 1 min, 60C for 1 min, 72Cspecific subset of human lymphoid malignancies.
for 1 min, and a final extension step at 72C for 7 min.
Are D cyclins good targets in human cancer therapy?
Other mouse strains and cell linesAll proliferating cells, including cancer cells, express at least
Rag2/ mice were purchased from the Taconic Farms. Rag2/ or Rag2//
one type of D cyclin (Bartkova et al., 1995, 1998; Lukas et al., cyclin D3/ mice were injected intraperitoneally with 100 g of anti-CD3
1994, 1995; Tam et al., 1994; Tetsu and McCormick, 2003). Our antibody (145-2C11, PharMingen, San Diego, CA). p56LCK-deficient (Molina
et al., 1992) and p53-deficient (Nacht and Jacks, 1998) mice were purchasedcurrent understanding of the cell cycle progression is that at
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from the Jackson Laboratories. Transgenic line LGY4220, expressing wild- transduction by centrifugation at 2200 rpm for 1.5 hr at room temperature
type p56LCK kinase driven by the proximal lck promoter, was kindly provided with 6 g/ml polybrene. On day 5, 7  104 EGFP Lin cells were injected
by Dr. R. Perlmutter. intravenously into irradiated (500 rad) RAG-2/c/ hosts (Colucci et al.,
J.CaM1.6 cells (p56LCK-deficient derivative of Jurkat E6-1) were pur- 2000) (Taconic Farms). Two weeks after injection, and at biweekly intervals
chased from the ATCC. The Y505F constitutively activated mutant form of thereafter, peripheral blood was stained for CD4 and CD8 expression and
the p56LCK kinase, cloned in the retroviral expression vector pGFP-RV, was analyzed by flow cytometry.
kindly provided by Dr. Kenneth M. Murphy (Washington University School
of Medicine, St. Louis, MO). Three micrograms of the pGFP-LCKY505F or T cell leukemia samples and microarray hybridization
the corresponding empty vector were transfected into the phoenix retroviral Detailed information about T cell leukemia patients, RNA purification, mi-
packaging cell line using the Fugene 6 reagent (Roche) according to the croarray hybridization, and data acquisition have been described before
manufacturer instructions. 72 hr after transfection, culture supernatants were (Ferrando et al., 2002). Briefly, cryopreserved lymphoblast samples of 39
used to infect the J.Cam1.6 cells at the final concentration of 1 million cells/ T-ALL cases were obtained and global gene expression analysis was per-
ml for 4 hr in the presence of Polybrene (8 g/ml). RNA was isolated and formed using Affymetrix HU6800 arrays (Ferrando et al., 2002).
processed for Northern blotting.
The p56LCK-transformed cell lines LGF2046 and LGF10442 were derived Microarray data analysis
from thymic lymphomas explanted from transgenic mice that overexpressed Data reduction was performed by filtering the expression values from Affyme-
constitutively activated p56LCK transgene (p56LCKF505) driven by the p56LCK trix HU6800 arrays using Genecluster software 2.0 (floor 100, ceiling 16,000,
proximal promoter, as described (Lin and Abraham, 1997). Cells were cul- fold difference 5, max-min difference 500). Data of the 452 genes that
tured for 18 hr in the presence of the Src-family kinase inhibitor PP1 (Hanke passed these filters was analyzed using Cluster software (Eisen et al., 1998).
et al., 1996). The inhibitor was then washed off and cells were harvested at the Expression values were adjusted by performing a log transformation followed
indicated time points, lysed, subjected to SDS-PAGE, and immunoblotted for by normalization and mean centering of the genes. Hierarchical clustering
cyclin D3 protein. of genes on these adjusted expression values across the 39 samples ana-
lyzed was performed using correlation (uncentered) as similarity metric, and
Flow cytometry and FACS the dendrogram resulting from this analysis was visualized using Treeview.
The following monoclonal antibodies were used: anti-CD3 (145-2C11), anti- Nearest neighbor analysis using the signal-to-noise statistics was performed
CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD25 (7D4), anti-CD44 (IM7), anti- to identify genes associated with cyclin D3 (Golub et al., 1999). Gene-Cluster
TCR	 (GL3), anti-TCR (H57-597), and anti-Pan-NK cells (DX5), all from analysis software and Cluster and Treeview programs are available together
PharMingen (San Diego, CA). These antibodies were directly coupled to with detailed instructions for microarray data analysis at http://www-
phycoerythtin (PE), fluorescein isothiocyanate (FITC), Cy-Chrome, or allo- genome.wi.mit.edu/cancer/software/software.html and http://rana.lbl.gov/
phycocyanin (APC). EisenSoftware.htm, respectively.
To sort thymocytes into different populations, cells were first stained
with biotinylated anti-CD4 and anti-CD8, followed by depletion with streptav- siRNA against cyclin D3
idin-conjugated magnetic beads (Dynal, Oslo, Norway). Depleted cells were To target cyclin D3 expression, siRNA sequences were designed against
then stained with anti-CD4-PE, anti-CD8-PE, anti-DX5-PE, anti-TCR	-PE, the 5
-AAGGAUCUUUGUGGCCAAGGA-3
 sequence of human cyclin D3
anti-CD44-Cy-Chrome, and anti-CD25-FITC, and PE-negative cells were transcript. Oligonucleotides were cloned into pMKO.1 retroviral vector, yield-
gated and sorted. Immature single-positive cells were defined, as ing pMKO.1-D3. T-ALL lines (CEM, Molt 15, Molt 4, P12-Ichikawa,
CD4CD8TCR. Sorted cells were processed immediately for Western RPMI8402, PF382, Jurkat, HPB ALL, KE-37, CML-T1, SUP-T1, and MKB-1),
or Northern blot analyses. To measure the fraction of proliferating cells, control 	 T-ALL lines (Loucy and PEER), and control B cell lines (2138C,
sorted thymocytes were fixed with 0.5% paraformaldehyde for 15 min on ice. JVM2, Granta, and Daudi) were grown in 10% calf serum in RPMI, infected
After fixation, cells were resuspended in a staining medium that consisted of with pMKO.1 or with pMKO.1-D3 retroviruses, and selected in medium
50 g/ml of propidium iodide and 250 g/ml of RNase A, then incubated containing 1–3 g/ml puromycin for 2 to 5 days, and the fraction of cells in
at 37C for 30 min. different phases of the cell cycle was determined by propidium iodide stain-
Flow cytometric analyses were done on a FACScalibur cytometer (Beck- ing followed by FACS. Gating was done on live cells.
ton Dickinson, San Jose, CA) and modeled with the MoDFit program. Cells
were sorted by a MoFlo cell sorter (Cytomation, Fort Collins, CO). Acknowledgments
Western and Northern blotting We thank Dr. R.A. Weinberg, in whose laboratory this work was initiated,
Protein extracts were prepared from sorted thymocytes, separated using J. Liu-Donaher for blastocysts injections, T. Look, C. Lopez-Rodriguez, F.
10% SDS-PAGE, transferred to Immobilion-P membrane (Millipore), and Gounari, A. Rao, N. Rao, H. Band, R.H. Medema, R. Bronson, E. Yu, W.
probed with an anti-cyclin D3 (C-16), anti-cyclin D2 (M-20) anti-cyclin D1, Hahn, A. Hsieh, W. Sellers, and the members of the Sicinski laboratory for
anti-CDK4 (Santa Cruz Biotechnology), and anti-actin (Chemicon) antibod- help and advice. This work was supported by an NIH R01 grant CA85296
ies. As a secondary antibody, peroxidase-conjugated IgG (BioRad) was (to P.S.). L.L.C. held Human Frontiers Science Postdoctoral Fellowship.
used, followed by enhanced chemiluminescence (ECL) detection (Sigma). A.A.F. was a fellow of the Leukemia Society. I.A. is supported by the Cancer
Northern blot analyses were performed as described (Yu et al., 2001). Research Institute and the Leukemia Research Foundation.
Transduction of bone marrow with Notch
A cassette encoding the constitutively active form of Notch-1 (kindly pro-
vided by I. Screpanti) was cloned upstream of an EGFP construct containing Received: July 24, 2003
an internal ribosomal entry site (IRES, Clontech, Palo Alto, CA). The entire Revised: September 29, 2003
cassette (or only the IRES-EGFP portion as a control) was inserted into a Published: December 22, 2003
modified MMLV-based retroviral vector (kindly provided by R. Mulligan).
Retroviral supernatants were produced by transient transfection of the ret- References
roviral vector and packaging plasmids (Ory et al., 1996) into the human
embryonic kidney epithelial cell line 293T. Supernatants were concentrated
Abraham, K., Levin, S., Marth, J., Forbush, K., and Perlmutter, R. (1991).by ultracentrifugation and stored at 80C. Bone marrow transduction was
Thymic tumorigenesis induced by overexpression of p56lck. Proc. Natl.done as previously described (Aifantis et al., 2002). Briefly, lineage negative
Acad. Sci. USA 88, 3977–3981.
(CD3, TCR, Gr-1, Ter-119, Mac-1, DX5, and CD19-negative) bone marrow
cells were sorted from cyclin D3/ and cyclin D3/ mice and cultured in Aifantis, I., Borowski, C., Gounari, F., Lacorazza, H., Nikolich-Zugich, J., and
the presence of IL-7, SCF, Flt3L, and IL-6 (all from R&D Systems, Minneapo- von Boehmer, H. (2002). A critical role for the cytoplasmic tail of pTalpha in
T lymphocyte development. Nat. Immunol. 3, 483–488.lis, MN). On days 2 and 4 after sorting, cells were subject to retroviral
CANCER CELL : DECEMBER 2003 459
A R T I C L E
Allman, D., Karnell, F., Punt, J., Bakkour, S., Xu, L., Myung, P., Koretzky, Ferrando, A., Neuberg, D., Staunton, J., Loh, M., Huard, C., Raimondi, S.,
Behm, F., Pui, C., Downing, J., Gilliland, D., et al. (2002). Gene expressionG., Pui, J., Aster, J., and Pear, W. (2001). Separation of Notch1 promoted
lineage commitment and expansion/transformation in developing T cells. J. signatures define novel oncogenic pathways in T cell acute lymphoblastic
leukemia. Cancer Cell 1, 75–87.Exp. Med. 194, 99–106.
Aster, J., Xu, L., Karnell, F., Patriub, V., Pui, J., and Pear, W. (2000). Essential Filipits, M., Jaeger, U., Pohl, G., Stranzl, T., Simonitsch, I., Kaider, A., Skrabs,
C., and Pirker, R. (2002). Cyclin D3 is a predictive and prognostic factor inroles for ankyrin repeat and transactivation domains in induction of T-cell
leukemia by notch1. Mol. Cell. Biol. 20, 7505–7515. diffuse large B-cell lymphoma. Clin. Cancer Res. 8, 729–733.
Fujii, M., Ishiguro, R., Yamashita, T., and Tashiro, M. (2001). Cyclin D1Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. (1995). Cyclin D1 onco-
protein aberrantly accumulates in malignancies of diverse histogenesis. On- amplification correlates with early recurrence of squamous cell carcinoma
of the tongue. Cancer Lett. 172, 187–192.cogene 10, 775–778.
Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. (1998). Cyclin D3: require- Golub, T., Slonim, D., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov,
J., Coller, H., Loh, M., Downing, J., Caligiuri, M., et al. (1999). Molecularment for G1/S transition and high abundance in quiescent tissues suggest
a dual role in proliferation and differentiation. Oncogene 17, 1027–1037. classification of cancer: class discovery and class prediction by gene expres-
sion monitoring. Science 286, 531–537.
Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C., and
Peters, G. (1994). CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset Hanke, J., Gardner, J., Dow, R., Changelian, P., Brissette, W., Weringer, E.,
Pollok, B., and Connelly, P. (1996). Discovery of a novel, potent, and Srcof the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9,
71–79. family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent
T cell activation. J. Biol. Chem. 271, 695–701.
Bellavia, D., Campese, A., Alesse, E., Vacca, A., Felli, M., Balestri, A., Stop-
pacciaro, A., Tiveron, C., Tatangelo, L., Giovarelli, M., et al. (2000). Constitu- Hedberg, Y., Roos, G., Ljungberg, B., and Landberg, G. (2002). Cyclin D3
protein content in human renal cell carcinoma in relation to cyclin D1 andtive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 trans-
genic mice. EMBO J. 19, 3337–3348. clinico-pathological parameters. Acta Oncol. 41, 175–181.
Hoffman, E., Passoni, L., Crompton, T., Leu, T., Schatz, D., Koff, A., Owen,Bellavia, D., Campese, A., Checquolo, S., Balestri, A., Biondi, A., Cazzaniga,
G., Lendahl, U., Fehling, H., Hayday, A., Frati, L., et al. (2002). Combined M., and Hayday, A. (1996). Productive T-cell receptor beta-chain gene re-
arrangement: coincident regulation of cell cycle and clonality during develop-expression of pTalpha and Notch3 in T cell leukemia identifies the require-
ment of preTCR for leukemogenesis. Proc. Natl. Acad. Sci. USA 99, 3788– ment in vivo. Genes Dev. 10, 948–962.
3793.
Houldsworth, J., Reuter, V., Bosl, G., and Chaganti, R. (1997). Aberrant
expression of cyclin D2 is an early event in human male germ cell tumorigene-Buschges, R., Weber, R., Actor, B., Lichter, P., Collins, V., and Reifenberger,
G. (1999). Amplification and expression of cyclin D genes (CCND1, CCND2 sis. Cell Growth Differ. 8, 293–299.
and CCND3) in human malignant gliomas. Brain Pathol. 9, 435–442; discus-
Ito, Y., Takeda, T., Wakasa, K., Tsujimoto, M., and Matsuura, N. (2001).sion 432–33.
Expression and possible role of cyclin D3 in human pancreatic adenocarci-
noma. Anticancer Res. 21, 1043–1048.Cheung, T., Yu, M., Lo, K., Yim, S., Chung, T., and Wong, Y. (2001). Alteration
of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett.
Kato, J., Matsuoka, M., Strom, D., and Sherr, C. (1994). Regulation of cyclin166, 199–206.
D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 14,
2713–2721.Colucci, F., Guy-Grand, D., Wilson, A., Turner, M., Schweighoffer, E., Tybu-
lewicz, V., and Di Santo, J. (2000). A new look at Syk in alpha beta and
Lammie, G., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michalides, R.,gamma delta T cell development using chimeric mice with a low competitive
Dickson, C., Arnold, A., and Peters, G. (1991). D11S287, a putative oncogenehematopoietic environment. J. Immunol. 164, 5140–5145.
on chromosome 11q13, is amplified and expressed in squamous cell and
mammary carcinomas and linked to BCL-1. Oncogene 6, 439–444.Delmer, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A.,
Marie, J., and Zittoun, R. (1995). Overexpression of cyclin D2 in chronic
Levelt, C., Mombaerts, P., Iglesias, A., Tonegawa, S., and Eichmann, K.B-cell malignancies. Blood 85, p2870–p2876.
(1993). Restoration of early thymocyte differentiation in T-cell receptor beta-
chain-deficient mutant mice by transmembrane signaling through CD3 epsi-Di Santo, J., Radtke, F., and Rodewald, H. (2000). To be or not to be a
pro-T? Curr. Opin. Immunol. 12, 159–165. lon. Proc. Natl. Acad. Sci. USA 90, 11401–11405.
Levelt, C., Mombaerts, P., Wang, B., Kohler, H., Tonegawa, S., Eichmann,Dickson, C., Fantl, V., Gillett, C., Brookes, S., Bartek, J., Smith, R., Fisher,
C., Barnes, D., and Peters, G. (1995). Amplification of chromosome band K., and Terhorst, C. (1995). Regulation of thymocyte development through
CD3: functional dissociation between p56lck and CD3 sigma in early thymic11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 90,
43–50. selection. Immunity 3, 215–222.
Liao, M., Zhang, X., Hill, R., Gao, J., Qumsiyeh, M., Nichols, W., and VanDyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev.
12, p2245–p2262. Dyke, T. (1998). No requirement for V(D)J recombination in p53-deficient
thymic lymphoma. Mol. Cell. Biol. 18, 3495–3501.
Eisen, M., Spellman, P., Brown, P., and Botstein, D. (1998). Cluster analysis
and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA Lin, K., and Abraham, K. (1997). Targets of p56(lck) activity in immature
thymoblasts: stimulation of the Ras/Raf/MAPK pathway. Int. Immunol. 9,95, 14863–14868.
291–306.
Engel, I., and Murre, C. (2001). The function of E- and Id proteins in lympho-
cyte development. Nat. Rev. Immunol. 1, 193–199. Lukas, J., Pagano, M., Staskova, Z., Draetta, G., and Bartek, J. (1994). Cyclin
D1 protein oscillates and is essential for cell cycle progression in human
Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. (1995). Mice tumour cell lines. Oncogene 9, 707–718.
lacking cyclin D1 are small and show defects in eye and mammary gland
development. Genes Dev. 9, 2364–2372. Lukas, J., Bartkova, J., Welcker, M., Petersen, O., Peters, G., Strauss, M.,
and Bartek, J. (1995). Cyclin D2 is a moderately oscillating nucleoprotein
Fehling, H., Krotkova, A., Saint-Ruf, C., and von Boehmer, H. (1995). Crucial required for G1 phase progression in specific cell types. Oncogene 10,
role of the pre-T-cell receptor alpha gene in development of alpha beta but 2125–2134.
not gamma delta T cells. Nature 375, 795–798.
Matsushime, H., Ewen, M., Strom, D., Kato, J., Hanks, S., Roussel, M., and
Fehling, H., Iritani, B., Krotkova, A., Forbush, K., Laplace, C., Perlmutter, R., Sherr, C. (1992). Identification and properties of an atypical catalytic subunit
and von Boehmer, H. (1997). Restoration of thymopoiesis in pT alpha/ (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71, 323–334.
mice by anti-CD3epsilon antibody treatment or with transgenes encoding
activated Lck or tailless pT alpha. Immunity 6, 703–714. Matsushime, H., Quelle, D., Shurtleff, S., Shibuya, M., Sherr, C., and Kato,
460 CANCER CELL : DECEMBER 2003
A R T I C L E
J. (1994). D-type cyclin-dependent kinase activity in mammalian cells. Mol. Shaughnessy, J., Jr., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., Sawyer,
J., Barlogie, B., Bergsagel, P., and Kuehl, M. (2001). Cyclin D3 at 6p21 isCell. Biol. 14, 2066–2076.
dysregulated by recurrent chromosomal translocations to immunoglobulin
Meyerson, M., and Harlow, E. (1994). Identification of G1 kinase activity for loci in multiple myeloma. Blood 98, 217–223.
cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14, 2077–2086.
Sherr, C., and Roberts, J. (1999). CDK inhibitors: positive and negative
Molina, T., Kishihara, K., Siderovski, D., van Ewijk, W., Narendran, A., Timms, regulators of G1-phase progression. Genes Dev. 13, 1501–1512.
E., Wakeham, A., Paige, C., Hartmann, K., Veillette, A., et al. (1992). Profound
Shinkai, Y., and Alt, F. (1994). CD3 epsilon-mediated signals rescue theblock in thymocyte development in mice lacking p56lck. Nature 357, 161–
development of CD4CD8 thymocytes in RAG-2/ mice in the absence164.
of TCR beta chain expression. Int. Immunol. 6, 995–1001.
Mombaerts, P., Iacomini, J., Johnson, R., Herrup, K., Tonegawa, S., and
Shinkai, Y., Rathbun, G., Lam, K., Oltz, E., Stewart, V., Mendelsohn, M.,Papaioannou, V. (1992). RAG-1-deficient mice have no mature B and T
Charron, J., Datta, M., Young, F., Stall, A., et al. (1992). RAG-2-deficientlymphocytes. Cell 68, 869–877.
mice lack mature lymphocytes owing to inability to initiate V(D)J re-
arrangement. Cell 68, 855–867.Mombaerts, P., Anderson, S., Perlmutter, R., Mak, T., and Tonegawa, S.
(1994). An activated lck transgene promotes thymocyte development in
Sicinski, P., Liu Donaher, J., Parker, S., Li, T., Fazeli, A., Gardner, H., Haslam,RAG-1 mutant mice. Immunity 1, 261–267.
S., Bronson, R., Elledge, S., and Weinberg, R. (1995). Cyclin D1 provides a
link between development and oncogenesis in the retina and breast. CellMotokura, T., and Arnold, A. (1993). Cyclin D and oncogenesis. Curr. Opin.
82, 621–630.Genet. Dev. 3, 5–10.
Sicinski, P., Liu Donaher, J., Geng, Y., Parker, S., Gardner, H., Park, M.,Muljo, S., and Schlissel, M. (2000). Pre-B and pre-T-cell receptors: conserva-
Robker, R.L., Richards, J., McGinnis, L., Biggers, J., et al. (1996). Cyclintion of strategies in regulating early lymphocyte development. Immunol. Rev.
D2 is an FSH-responsive gene involved in gonadal cell proliferation and175, 80–93.
oncogenesis. Nature 384, 470–474.
Nacht, M., and Jacks, T. (1998). V(D)J recombination is not required for
Tam, S., Theodoras, A., Shay, J., Draetta, G., and Pagano, M. (1994). Differ-the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9,
ential expression and regulation of Cyclin D1 protein in normal and tumor131–138.
human cells: association with Cdk4 is required for Cyclin D1 function in G1
progression. Oncogene 9, 2663–2674.Ordentlich, P., Lin, A., Shen, C., Blaumueller, C., Matsuno, K., Artavanis-
Tsakonas, S., and Kadesch, T. (1998). Notch inhibition of E47 supports the Tetsu, O., and McCormick, F. (2003). Proliferation of cancer cells despite
existence of a novel signaling pathway. Mol. Cell. Biol. 18, 2230–2239. CDK2 inhibition. Cancer Cell 3, 233–245.
Ortega, S., Malumbres, M., and Barbacid, M. (2002). Cyclin D-dependent Weinstat-Saslow, D., Merino, M., Manrow, R., Lawrence, J., Bluth, R., Witten-
kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602, 73–87. bel, K., Simpson, J., Page, D., and Steeg, P. (1995). Overexpression of cyclin
D mRNA distinguishes invasive and in situ breast carcinomas from non-Ory, D., Neugeboren, B., and Mulligan, R. (1996). A stable human-derived
malignant lesions. Nat. Med. 1, 1257–1260.packaging cell line for production of high titer retrovirus/vesicular stomatitis
virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400–11406. Withers, D., Harvey, R., Faust, J., Melnyk, O., Carey, K., and Meeker, T.
(1991). Characterization of a candidate bcl-1 gene. Mol. Cell. Biol. 11, 4846–
Pui, J., Allman, D., Xu, L., DeRocco, S., Karnell, F., Bakkour, S., Lee, J., 4853.
Kadesch, T., Hardy, R., Aster, J., and Pear, W. (1999). Notch1 expression
in early lymphopoiesis influences B versus T lineage determination. Immunity Yu, Q., Geng, Y., and Sicinski, P. (2001). Specific protection against breast
cancers by cyclin D1 ablation. Nature 411, 1017–1021.11, 299–308.
CANCER CELL : DECEMBER 2003 461
